Nanomedicines for cancer therapy: current status, challenges and future prospects

Gizem Bor; Intan Diana Mat Azmi; Anan Yaghmur

doi:10.4155/tde-2018-0062

Nanomedicines for cancer therapy: current status, challenges and future prospects

Gizem Bor, Intan Diana Mat Azmi, Anan Yaghmur

43 Citationer (Scopus)

Abstract

The emergence of nanomedicine as an innovative and promising alternative technology shows many advantages over conventional cancer therapies and provides new opportunities for early detection, improved treatment, and diagnosis of cancer. Despite the cancer nanomedicines' capability of delivering chemotherapeutic agents while providing lower systemic toxicity, it is paramount to consider the cancer complexity and dynamics for bridging the translational bench-to-bedside gap. It is important to conduct appropriate investigations for exploiting the tumor microenvironment, and achieving a more comprehensive understanding of the fundamental biological processes in cancer and their roles in modulating nanoparticle-protein interactions, blood circulation, and tumor penetration. This review provides an overview of the current cancer nanomedicines, the major challenges, and the future opportunities in this research area.

Originalsprog	Engelsk
Tidsskrift	Therapeutic Delivery
Vol/bind	10
Udgave nummer	2
Sider (fra-til)	113-132
Antal sider	20
ISSN	2041-5990
DOI	https://doi.org/10.4155/tde-2018-0062
Status	Udgivet - feb. 2019

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.4155/tde-2018-0062

Citationsformater

@article{f881f30797f64380b13e3129a96a9a0c,

title = "Nanomedicines for cancer therapy: current status, challenges and future prospects",

abstract = "The emergence of nanomedicine as an innovative and promising alternative technology shows many advantages over conventional cancer therapies and provides new opportunities for early detection, improved treatment, and diagnosis of cancer. Despite the cancer nanomedicines' capability of delivering chemotherapeutic agents while providing lower systemic toxicity, it is paramount to consider the cancer complexity and dynamics for bridging the translational bench-to-bedside gap. It is important to conduct appropriate investigations for exploiting the tumor microenvironment, and achieving a more comprehensive understanding of the fundamental biological processes in cancer and their roles in modulating nanoparticle-protein interactions, blood circulation, and tumor penetration. This review provides an overview of the current cancer nanomedicines, the major challenges, and the future opportunities in this research area.",

author = "Gizem Bor and {Mat Azmi}, {Intan Diana} and Anan Yaghmur",

year = "2019",

month = feb,

doi = "10.4155/tde-2018-0062",

language = "English",

volume = "10",

pages = "113--132",

journal = "Therapeutic Delivery",

issn = "2041-5990",

publisher = "Future Science",

number = "2",

}

TY - JOUR

T1 - Nanomedicines for cancer therapy

T2 - current status, challenges and future prospects

AU - Bor, Gizem

AU - Mat Azmi, Intan Diana

AU - Yaghmur, Anan

PY - 2019/2

Y1 - 2019/2

N2 - The emergence of nanomedicine as an innovative and promising alternative technology shows many advantages over conventional cancer therapies and provides new opportunities for early detection, improved treatment, and diagnosis of cancer. Despite the cancer nanomedicines' capability of delivering chemotherapeutic agents while providing lower systemic toxicity, it is paramount to consider the cancer complexity and dynamics for bridging the translational bench-to-bedside gap. It is important to conduct appropriate investigations for exploiting the tumor microenvironment, and achieving a more comprehensive understanding of the fundamental biological processes in cancer and their roles in modulating nanoparticle-protein interactions, blood circulation, and tumor penetration. This review provides an overview of the current cancer nanomedicines, the major challenges, and the future opportunities in this research area.

AB - The emergence of nanomedicine as an innovative and promising alternative technology shows many advantages over conventional cancer therapies and provides new opportunities for early detection, improved treatment, and diagnosis of cancer. Despite the cancer nanomedicines' capability of delivering chemotherapeutic agents while providing lower systemic toxicity, it is paramount to consider the cancer complexity and dynamics for bridging the translational bench-to-bedside gap. It is important to conduct appropriate investigations for exploiting the tumor microenvironment, and achieving a more comprehensive understanding of the fundamental biological processes in cancer and their roles in modulating nanoparticle-protein interactions, blood circulation, and tumor penetration. This review provides an overview of the current cancer nanomedicines, the major challenges, and the future opportunities in this research area.

U2 - 10.4155/tde-2018-0062

DO - 10.4155/tde-2018-0062

M3 - Journal article

C2 - 30678550

SN - 2041-5990

VL - 10

SP - 113

EP - 132

JO - Therapeutic Delivery

JF - Therapeutic Delivery

IS - 2

ER -

Nanomedicines for cancer therapy: current status, challenges and future prospects

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater